全文获取类型
收费全文 | 863篇 |
免费 | 49篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 36篇 |
妇产科学 | 11篇 |
基础医学 | 84篇 |
口腔科学 | 51篇 |
临床医学 | 87篇 |
内科学 | 219篇 |
皮肤病学 | 11篇 |
神经病学 | 15篇 |
特种医学 | 228篇 |
外科学 | 42篇 |
综合类 | 16篇 |
预防医学 | 25篇 |
眼科学 | 15篇 |
药学 | 31篇 |
肿瘤学 | 43篇 |
出版年
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 10篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 15篇 |
2014年 | 21篇 |
2013年 | 20篇 |
2012年 | 24篇 |
2011年 | 17篇 |
2010年 | 37篇 |
2009年 | 30篇 |
2008年 | 14篇 |
2007年 | 25篇 |
2006年 | 11篇 |
2005年 | 15篇 |
2004年 | 12篇 |
2003年 | 7篇 |
2002年 | 15篇 |
2001年 | 12篇 |
2000年 | 5篇 |
1999年 | 10篇 |
1998年 | 47篇 |
1997年 | 57篇 |
1996年 | 53篇 |
1995年 | 50篇 |
1994年 | 49篇 |
1993年 | 32篇 |
1992年 | 15篇 |
1991年 | 13篇 |
1990年 | 17篇 |
1989年 | 22篇 |
1988年 | 33篇 |
1987年 | 20篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 14篇 |
1983年 | 18篇 |
1982年 | 18篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 2篇 |
1978年 | 7篇 |
1977年 | 10篇 |
1976年 | 15篇 |
1975年 | 4篇 |
1970年 | 2篇 |
1968年 | 1篇 |
排序方式: 共有918条查询结果,搜索用时 15 毫秒
91.
Hypogonadotropic hypogonadism (HH), consequent to congenital or acquired disorders of the hypothalamic–pituitary axis, presents as absent/delayed/arrested sexual maturation and infertility. Optimal management includes: (a) confirmation of the diagnosis and prognosis, (b) timing and choice of therapeutic intervention and (c) consideration of future fertility prospects. Therapy is usually initiated with testosterone to induce development of secondary sexual characteristics, taking the patient (often diagnosed late) through puberty. Monitoring of the impact of the condition on long‐term health and psychosocial function is necessary. Treatment is likely to be life‐long, requiring regular monitoring for its optimization and avoidance of adverse responses. Induction of spermatogenesis requires either pulsatile gonadotropin releasing hormone (GnRH) or gonadotropin administration. Gonadotropins can be self‐administered subcutaneously and are not inferior to the more costly GnRH. ‘Reversible genetic hypogonadotropic hypogonadism’ is a recently described entity which has implications for the long‐term management of patients with HH. 相似文献
92.
93.
Jean‐Philippe Brandel MD Craig A. Heath MD Mark W. Head PhD Etienne Levavasseur PhD Richard Knight MD Jean‐Louis Laplanche PharmD PhD Jan PM. Langeveld PhD James W. Ironside MD Jean‐Jacques Hauw MD Jan Mackenzie Annick Alpérovitch MD Robert G. Will MD Stéphane Haïk MD PhD 《Annals of neurology》2009,65(3):249-256
94.
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications 总被引:1,自引:0,他引:1
Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y1 , P2Y12 , CYP2C9, CYP3A4 and CYP3A5 genotypes. 相似文献
95.
96.
The unravelling of the genetic basis of the hypogonadotrophic hypogonadal disorders, including Kallmann syndrome (KS), has led to renewed interest into the developmental biology of gonadotrophin-releasing hormone (GnRH) neurones and, more generally, into the molecular mechanisms of reproduction. KS is characterised by the association of GnRH deficiency with diminished olfaction. Until recently, only two KS-associated genes were known: KAL1 and KAL2. KAL1 encodes the cell membrane and extracellular matrix-associated secreted protein anosmin-1 which is implicated in the X-linked form of KS. Anosmin-1 shows high affinity binding to heparan sulphate (HS) and its function remains the focus of ongoing investigation, although a role in axonal guidance and neuronal migration, which are processes essential for normal GnRH ontogeny and olfactory bulb histogenesis, has been suggested. KAL2, identified as the fibroblast growth factor receptor 1 (FGFR1) gene, has now been recognised to be the underlying genetic defect for an autosomal dominant form of KS. The diverse signalling pathways initiated upon FGFR activation can elicit pleiotropic cellular responses depending on the cellular context. Signalling through FGFR requires HS for receptor dimerisation and ligand binding. Current evidence supports a HS-dependent interaction between anosmin-1 and FGFR1, where anosmin-1 serves as a co-ligand activator enhancing the signal activity, the finer details of whose mechanism remain the subject of intense investigation. Recently, mutations in the genes encoding prokineticin 2 (PK2) and prokineticin receptor 2 (PKR2) were reported in a cohort of KS patients, further reinforcing the view of KS as a multigenic trait involving divergent pathways. Here, we review the historical and current understandings of KS and discuss the latest findings from the molecular and cellular studies of the KS-associated proteins, and describe the evidence that suggests convergence of several of these pathways during normal GnRH and olfactory neuronal ontogeny. 相似文献
97.
RD Vaithilingam SH Safii NA Baharuddin LP Karen‐Ng R Saub F Ariffin H Ramli A Sharifuddin MFH Hidayat R Raman YK Chan NA Rani RA Rahim N Shahruddin SC Cheong PM Bartold RB Zain 《Oral diseases》2015,21(1):e62-e69
Periodontal bio‐repositories, which allow banking of clinically validated human data and biological samples, provide an opportunity to derive biomarkers for periodontal diagnosis, prognosis and therapeutic activities which are expected to improve patient management. This article presents the establishing of the Malaysian Periodontal Database and Biobank System (MPDBS) which was initiated in 2011 with the aim to facilitate periodontal research. Partnerships were established with collaborating centres. Policies on specimen access, authorship and acknowledgement policies were agreed upon by all participating centres before the initiation of the periodontal biobank. Ethical approval for the collection of samples and data were obtained from institutional ethics review boards. A broad‐based approach for informed consent was used, which covered areas related to quality of life impacts, genetics and molecular aspects of periodontal disease. Sample collection and processing was performed using a standardized protocol. Biobanking resources such as equipment and freezers were shared with the Malaysian Oral Cancer Database and Tissue Bank System (MOCDTBS). In the development of the MPDBS, challenges that were previously faced by the MOCDTBS were considered. Future challenges in terms of ethical and legal issues will be faced when international collaborations necessitate the transportation of specimens across borders. 相似文献
98.
99.
100.
Marjolein H Willemsen Bridget A Fernandez Carlos A Bacino Erica Gerkes Arjan PM de Brouwer Rolph Pfundt Birgit Sikkema-Raddatz Stephen W Scherer Christian R Marshall Lorraine Potocki Hans van Bokhoven Tjitske Kleefstra 《European journal of human genetics : EJHG》2010,18(4):429-435
The clinical use of array comparative genomic hybridization in the evaluation of patients with multiple congenital anomalies and/or mental retardation has recently led to the discovery of a number of novel microdeletion and microduplication syndromes. We present four male patients with overlapping molecularly defined de novo microdeletions of 16q24.3. The clinical features observed in these patients include facial dysmorphisms comprising prominent forehead, large ears, smooth philtrum, pointed chin and wide mouth, variable cognitive impairment, autism spectrum disorder, structural anomalies of the brain, seizures and neonatal thrombocytopenia. Although deletions vary in size, the common region of overlap is only 90 kb and comprises two known genes, Ankyrin Repeat Domain 11 (ANKRD11) (MIM 611192) and Zinc Finger 778 (ZNF778), and is located approximately 10 kb distally to Cadherin 15 (CDH15) (MIM 114019). This region is not found as a copy number variation in controls. We propose that these patients represent a novel and distinctive microdeletion syndrome, characterized by autism spectrum disorder, variable cognitive impairment, facial dysmorphisms and brain abnormalities. We suggest that haploinsufficiency of ANKRD11 and/or ZNF778 contribute to this phenotype and speculate that further investigation of non-deletion patients who have features suggestive of this 16q24.3 microdeletion syndrome might uncover other mutations in one or both of these genes. 相似文献